Fully funded by 
Content independently selected
HPV vaccination, testing best for preventing cervical cancer.
Findings from ACTLACC trial.
Platinum-based doublet therapy was less tolerable.
Similar local disease control, cancer-specific survival vs LDR brachytherapy.
Exploring the impacts of the 2012 Health and Social Care Act reforms on clinical activity in the English NHS.
Announcements pertaining to HPV vaccination and bowel screening.
PIK3CA mutation status predicted resistance to cetuximab.
Phase 2 trial shows efficacy regardless of high-risk HPV type.
Data from the phase 2 pembrolizumab KEYNOTE-158 basket study.
HIV coinfection increases HPV-related cancer risk.
The campaign aims to improve uptake by encouraging women to attend screening.
Safety, efficacy not established; some evidence points to lower long-term survival.
Rapid worldwide scale-up could virtually eliminate the disease by century's end.
Findings affirm public health benefits.
Findings from the pilot project strongly support an extension of screening intervals.
Experts say a new algorithm could revolutionise cervical cancer screening.
Overall cancer risk boosted by 28%.
